Phase 2 Study of Intravenous Administration of a Wild-Type Reovirus (REOLYSIN) in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Trial Profile

Phase 2 Study of Intravenous Administration of a Wild-Type Reovirus (REOLYSIN) in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Pelareorep (Primary) ; Carboplatin; Paclitaxel
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Aug 2011 Planned end date changed from 1 Oct 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
    • 25 May 2011 Planned End Date changed from 1 May 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top